The Hill ran Yet Another Article on how compounded versions of GLP-1 drugs are spreading — a boon for patients but a bugaboo for pharma companies. The article gave a bit too much space to pharma’s tired (and baseless) arguments about safety and compounding regulation, but at least it quoted Scott explaining how prescriptions for compounded drugs actually work.